Efficacy and safety of adalimumab in pediatric patients with Crohn's disease: A systematic review and meta-analysis.

ABSTRACT:

Purpose

There is currently no curative treatment for childhood Crohn's disease (CD). This meta-analysis aimed to validate the efficacy and safety of adalimumab (ADA) in pediatric patients with CD.

Materials and methods

We searched all relevant studies in the PubMed, Web of Science, Embase, and Cochrane Library databases. The primary outcomes were induction (≤ 12 weeks) and maintenance (up to 48 weeks) of remission and response. Secondary outcomes were severe adverse events and opportunistic infections to ADA. The Cochrane bias assessment tool was used to assess the risk of bias in randomized controlled trials. The methodological quality of the single-arm studies was assessed using the methodological index for non-randomized studies tool.

Results

Ten clinical trials in

SUBMITTER: Chen B 

PROVIDER: S-EPMC10873464 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature